Pathology of multiple sclerosis

Handbook of Multiple Sclerosis, Third Edition

Volumn , Issue , 2001, Pages 289-324

  Prineas, John W ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85024917181     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (191)

1. Brosnan CF, Raine CS. Mechanisms of immune injury in multiple sclerosis. Brain Pathology 1996; 6:243-257.
2. Lumsden CE. The neuropathology of multiple sclerosis. In: Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology, vol 9. Amsterdam: North Holland, 1970, pp 217-309.
3. Brück W, Friede RL. Anti-macrophage CR3 antibody blocks myelin phagocytosis by macrophages in vitro. Acta Neuropathol 1990; 80:415-418.
4. Brück W, Brück Y, Diederich U, Piddlesden SJ. The membrane attack complex of complement mediates peripheral nervous system demyelination in vitro. Acta Neuropathol 1995; 90:601-607.
5. Prineas JW. The neuropathology of multiple sclerosis. In: Vinken PJ, Bruyn GW, Klawans GW, Koetsier JC, eds. Demyelinating Diseases: Handbook of Clinical Neurology, vol 47. Amsterdam: Elsevier, 1985, pp 213-257.
6. Lassmann H. Comparative Neuropathology of Chronic Experimental Allergic Encephalomyelitis and Multiple Sclerosis. Berlin: Springer-Verlag, 1983.
7. Compston DAS, Morgan BP, Campbell AK, Wilkins P, Cole G, Thomas ND, Jasani B. Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol Appl Neurobiol 1989; 15:307-317.
8. Allen IV, Millar JHD, Hutchinson MJ. General disease in 120 necropsy-proven cases of multiple sclerosis. Neuropathol Appl Neurobiol 1978; 4:279-284.
9. Pollock M, Calder C, Allpress S. Peripheral nerve abnormality in multiple sclerosis. Ann Neurol 1977; 2:41-48.
10. Cuzner ML, Norton WT. Biochemistry of demyelination. Brain Pathol 1996; 6:231-242.
11. Schoene WC, Carpenter S, Behan PO, Geschwind N. Onion bulb formations in the central and peripheral nervous system in association with multiple sclerosis and hypertrophic polyneuropathy. Brain 1977; 100:755-773.
12. Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, Opdenakker G, Newcombe J. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: Comparison of stages in lesion evolution. J Neuropathol Exp Neurol 1996; 55:1194-1204.
13. Barnard RO, Triggs M. Corpus callosum in multiple sclerosis. J Neurol Neurosurg Psychiatry 1974; 37:1259-1264.
14. Ulrich J, Groebke-Lorenz W. The optic nerve in multiple sclerosis: A morphological study with retrospective clinicopathological correlations. Neuroophthalmology 1983; 3:149-159.
15. Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry 1962; 25:315-320.
16. Dawson JW. The histology of multiple sclerosis. Trans R Soc Edinb 1916; 50:517-740. (With plates; reproduced by the Montreal Neurological Institute, Montreal, 1973.)
17. De Jong BA, Smith ME. A role for complement in phagocytosis of myelin. Neurochem Res 1997; 22:491-498.
18. Prineas JW, Barnard RO, Revesz T, Kwon EE, Sharer L, Cho E-S. Multiple sclerosis: Pathology of recurrent lesions. Brain 1993; 116:681-693.
19. Prineas JW, Wright RG. Macrophages, lymphocytes and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest 1978; 38:409-421.
20. Esiri MM, Reading MC. Macrophage populations associated with multiple sclerosis plaques. Neuropathol Appl Neurobiol 1987; 13:451-465.
21. Prineas JW. Multiple sclerosis: Presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science 1979; 203:1123-1125.
22. Barnes D, Munro PMG, Youl BD, Prineas JW, McDonald WI. The longstanding MS lesion: A quantitative MRI and electron microscopic study. Brain 1991; 114:1271-1280.
23. Prineas JW, Connell F. The fine structure of chronically active multiple sclerosis plaques. Neurology 1978; 28(9, part 2):68-75.
24. Raine CS. Membrane specializations between demyelinated axons and astroglia in chronic EAE lesions and multiple sclerosis plaques. Nature 1978; 275:326-327.
25. Prineas JW, Connell F. Remyelination in multiple sclerosis. Ann Neurol 1979; 5:22-31.
26. Suzuki K, Andrews JM. Waltz JM, Terry RD. Ultrastructural studies of multiple sclerosis. Lab Invest 1969; 20:444-454.
27. Esiri MM, Gay D. The immunocytochemistry of multiple sclerosis plaques. In: Raine CS, McFarland HF, Tourtellotte WW, eds. Multiple Sclerosis: Clinical and Pathological Basis. London, Weinheim, New York, Tokyo, Melbourne, Madras: Chapman and Hall Medical, 1997, pp 173-186.
28. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996; 272:50-54.
29. Prineas JW, Kwon EE, Cho E-S, Sharer LR. Continual breakdown and regeneration of myelin in progressive multiple sclerosis plaques. In: Scheinberg L, Raine CS, eds. Multiple sclerosis: experimental and clinical aspects. Ann NY Acad Sci 1984; 436:11-32.
30. Itoyama Y, Webster H de F, Richardson EP Jr, Trapp BD. Schwann cell remyelination of demyelinated axons in spinal cord multiple sclerosis lesions. Ann Neurol 1983; 14:339-346.
31. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120:393-399.
32. Gay FW, Drye TJ, Dick GWA, Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis: Identification and characterization of the primary demyelinating lesion. Brain 1997; 120:1461-1483.
33. Allen IV, McKeown SR. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 1979; 41:81-91.
34. Adams RD, Kubik CS. The morbid anatomy of the demyelinative diseases. Am J Med 1952; 12:510-546.
35. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis: Principles, problems and perspectives. Brain 1997; 120:865-916.
36. Prineas JW, Raine CS. Electron microscopy and immunoperoxidase studies of early multiple sclerosis lesions. Neurology 1976; 26(6, part 2):29-32.
37. Prineas JW, Graham JS. Multiple sclerosis: Capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann Neurol 1981; 10:149-158.
38. Woodroofe MN, Bellamy AS, Feldmann M, Davison AN, Cuzner ML. Immunocytochemical characterization of the immune reaction in the central nervous system in multiple sclerosis: Possible role for microglia in lesion growth. J Neurol Sci 1986; 74:135-152.
39. Prineas JW, Kwon EE, Goldenberg PZ, et al. Multiple sclerosis: Oligodendrocyte proliferation and differentiation in fresh lesions. Lab Invest 1989; 61:489-503.
40. Prineas JW, Barnard RO, Kwon EE, Sharer LR, Cho E-S. Multiple sclerosis: Remyelination of nascent lesions. Ann Neurology 1993; 33:137-151.
41. Brück W, Schmied M, Suchanek G, et al. Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol 1994; 35:65-73.
42. Ozawa K, Suchanek G, Breitschope H, Brück W, Budka H, Jellinger K, Lassmann H. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 1994; 117:1311-1322.
43. Moore GRW, Neumann PE, Suzuki K, Lijtmaer HN, Traugott U, Raine CS. Baló‘s concentric sclerosis: New observations on lesion development. Ann Neurol 1985; 17:604-611.
44. Morris CS, Esiri MM, Sprinkle TJ, Gregson N. Oligodendrocyte reactions and cell proliferation markers in human demyelinating diseases. Neurolopath Appl Neurobiol 1994; 20:272-281.
45. Burger D, Steck AJ, Bernard CCA, Kerlero de Rosbon. Human myelin/oligodendrocyte glycoprotein: A new member of the L2/HNK-1 family. J Neurochem 1993; 61:1822-1827.
46. Marburg O. Die sogenannte '‘akute multiple Sklerose’’ (encephalomyelitis periaxialis scleroticans). Jahrb Psychiatr Neurol (Leipzig) 1906; 27:213-311.
47. Baló J. Leucoencephalitis periaxialis concentrica. Magy Novosi Arch 1927; 28:108-124.
48. Dévic E. Myélite subaigüe compliquée de nérvite optique (abstr). Bull Méd (Paris) 1894; 8: 1033-1034.
49. Schilder P. Zur kenntnis der sogenannte diffusen sklerose. Z Neurol Psychiatr 1912; 10:1-60.
50. Hughes JT. Pathology of the Spinal Cord. London: Lloyd-Luke, 1966, pp 146-159.
51. Phadke JG, Best PV. Atypical and clinically silent multiple sclerosis: A report of 12 cases discovered unexpectedly at necropsy. J Neurol Neurosurg Psychiatry 1983; 46:414-420.
52. Kirk J, The fine structure of the CNS in multiple sclerosis: II. Vesicular demyelination in the acute case. Neuropathol Appl Neurobiol 1979; 5:289-294.
53. Voskuhl RR, McFarlin DE, Rhame L, Deibler G, Stone R, Maloni H, McFarland HF. A novel candidate autoantigen in a multiplex family with multiple sclerosis: T-lymphocytes specific for an MBP epitope unique to myelination are as prevalent as epitopes within 18.5 kd MBP. J Neuroimmunol 1993; 46:137-144.
54. Morariu M, Klutzow WF. Subclinical multiple sclerosis. J Neurol 1976; 213:71-76.
55. Harper CG. Acute central nervous system disorder mimicking stroke. Med J Aust 1981; 1: 136-138.
56. Lassmann H. Comparative Neuropathology of Chronic Experimental Allergic Encephalomyelitis and Multiple Sclerosis. Berlin-Heidelberg, New York, Tokyo: Springer, 1983.
57. Yao D-L, Webster H de F, Hudson LD et al. Concentric sclerosis (Baló): Morphometric and in situ hybridization study of lesions in six patients. Ann Neurol 1994; 35:18-30.
58. Poser CM. Myelinoclastic diffuse and transitional sclerosis. In: Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology, vol. 9: Multiple Sclerosis and Other Demyelinating Disease. Amsterdam: North Holland, 1970, pp. 469-484.
59. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994; 117:759-765.
60. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991; 29:53-62.
61. Zagzag D, Miller DC, Kleinman GM, Abati A, Donnenfeld H. Budzilovich GN. Demyelinating disease versus tremor in surgical neuropathology: Clues to a correct pathological diagnosis. Am J Surg Pathol 1993; 17:537-545.
62. Kepes JJ. Large focal tumor-like demyelinating lesions of the brain: Intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann Neurol 1993; 33:182-127.
63. Lee SC, Raine CS. Multiple sclerosis: Oligodendrocytes in active lesions do not express class II major histocompatability complex molecules. J Neuroimmunol 1989; 25:261-266.
64. Lee SC, Moore GRW, Golenwsky G, Raine CS. Multiple sclerosis: A role for astroglia in active demyelination suggested by class II MHC expression and ultrastructural study. J Neuropathol Exp Neurology 1990; 49:122-136.
65. Li H, Newcombe J, Groome NP, Cuzner ML. Characterization and distribution of phagocytic macrophages in multiple sclerosis plaques. Neuropathol Appl Neurobiol 1993; 19:214-223.
66. Uchimura I. Shiraki H. A contribution to the classification and the pathogenesis of demyelinating encephalomyelitis: With special reference to the central nervous system lesions caused by preventive inoculation against rabies. J Neuropathol Exp Neurol 1957; 16:139-208.
67. Link H. B cells and autoimmunity. In: Russell WC, ed. Molecular Biology of Multiple Sclerosis. New York: Wiley 1997, pp 161-190.
68. Piddlesden SJ, Lassmann H, Zimprich F, Morgan BP, Linington C. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol 1993; 143:555-564.
69. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis (review). Brain Pathol 1996; 6:259-274.
70. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules and multiple sclerosis lesions. J Neuropathol Exp Pathol 1996; 55:300-309.
71. Prineas JW, Kwon EE, Sternberger NH, Lennon VA. The distribution of myelin associated glycoprotein and myelin basic protein in actively demyelinating multiple sclerosis lesions. J Neuroimmunol 1984; 6:251-264.
72. Morgan BP, Campbell AK, Compston DA. Terminal component of complement (C9) in cerebrospinal fluid of patients with multiple sclerosis. Lancet 1984; 2:251-254.
73. Mosley K, Cuzner ML. Receptor-mediated phagocytes of myelin by macrophages and microglia: Effect of opsonization and receptor blocking agents. Neurochemistry 1996; 21:481-487.
74. Nyland H, Matre R, Mork S. Fc receptors on microglial lipophages in multiple sclerosis. N Engl J Med 1980; 302(2):120-121.
75. Johnson ES, Ludwin SK. The demonstration of recurrent demyelination and remyelination of axons in the central nervous system. Acta Neuropathol 1981; 53:93-98.
76. Rabb H, Michishita M, Sharma CP, Brown D, Arnaout MA. Cytoplasmic tails of human complement receptor type 3 (CR3, CD11b/CD18) regulate ligand avidity and the internalization of occupied receptors. J Immunol 1993; 151:990-1002.
77. Raine CS, Cannella B, Hauser SL, Genain CP. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: A case study for antigen-specific antibody mediation. Ann Neurol 1999; 46:144-160.
78. Bornstein, MB, Raine CS. Experimental allergic encephalomyelitis: Antiserum inhibition of myelination in vitro. Lab Invest 1970; 23:536-542.
79. Sanders ME, Alexander EL, Koski CL, Shin ML, Sano Y, Frank MM, Joiner KA. Terminal complement complexes (SC5b-9) in cerebrospinal fluid in autoimmune nervous system diseases. Ann NY Acad Sci 1988; 540:387.
80. Prineas JW, Kwon EE, Goldenberg PZ, Cho E-S, Sharer LR. Interaction of astrocytes and newly formed oligodendrocytes in resolving multiple sclerosis lesions. Lab Invest 1990; 63: 624-636.
81. Perry VH, Lund RD. Evidence that the lamina cribrosa prevents intraretinal myelination of retinal ganglion cell axons. J Neurocytol 1990; 19:265-272.
82. Kwon EE, Prineas JW. Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions: An immunohistochemical study. J Neuropathol Exp Neurol 1994; 53:625-636.
83. Sanders V, Conrad AJ, Tourtellotte WW. On classification of post-mortem multiple sclerosis plaques for neuroscientists. J Neuroimmunol 1993; 46:207-216.
84. Sellebjerg F, Christiansen M, Garred P. MBP, anti-MBP and anti-PLP antibodies, and intrathecal complement activation in multiple sclerosis. Mult Scler 1998; 4:127-131.
85. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. Multiple sclerosis: In situ evidence for antibody-and complement-mediated demyelination. Ann Neurol 1998; 43:465-471.
86. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338:278-285.
87. Traugott U, Reinherz EL, Raine CS. Multiple sclerosis: Distribution of T cells, T cell subsets, and Ia-positive macrophages in lesions of different ages. J Neuroimmunol 1983; 4:201-221.
88. Ulvestad E, Williams K, Mörk S, Antel J, Nyland H. Phenotypic differences between human monocyte/macrophage and microglial cells studied in vitro. J Neuopathol Exp Neurol 1994; 53:492-501.
89. van der Laan LJW, Ruucs SR, Weber KS, Lodder J, Dopp EA, Dijkstra CD. Macrophage phagocytosis of myelin in vitro determined by flow cytometry: Phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-a and nitric oxide. J Neuroimmunol 1996; 70:145-152.
90. Vanguri P, Shin ML. Hydrolysis of myelin basic protein in human myelin by terminal complement complexes. J Biol Chem 1988; 263:7228-7234.
91. Woodroofe MN, Cuzner ML. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: Detection by non-radioactive in situ hybridisation. Cytokine 1993; 5:583-588.
92. Schmidt S. Candidate autoantigens in multiple sclerosis. Mult Scler 1999; 5:147-160.
93. Lassmann H, Vass K. Are current immunological concepts of multiple sclerosis reflected by the immunopathology of its lesions? Springer Semin Immunopathol 1995; 17:77-87.
94. Sobel RA, Mitchell M, Fondren G. Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. Am J Pathol 1990; 136:1309-1316.
95. + oligodendrocytes in multiple sclerosis. Proc Natl Acad Sci USA 1991; 88:6452-6456.
96. Sobel RA, Hafler DA, Castro EE, Morimoto C, Weiner HL. The 2H4 (CD45R) antigen is selectively decreased in multiple sclerosis lesions. J Immunol 1988; 140:2210-2214.
97. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995; 37:424-435.
98. Hayashi T, Morimoto C, Burks JS, Kerr C, Hauser SL. Dual-label immunocytochemistry of the active multiple sclerosis lesion: Major histocompatability complex and activation antigens. Ann Neurol 1988; 24:523-531.
99. Duncan ID. Glial cell transplantation and remyelination of the central nervous system (review). Neuropathol Appl Neurobiol 1996; 22:87-100.
100. Linington C, Bradl M, Lassmann H, Brunner C, Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against myelin/oligodendrocyte glycoprotein. Am J Pathol 1988; 130:443-454.
101. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system. Neurology 1987; 37:1097-1102.
102. Raine CS, Wu E, Ivanyi J, Katz D, Brosnan CF. Multiple sclerosis: A protective or a pathogenic role for heat shock protein 60 in the central nervous system? Lab Invest 1996; 75: 109-123.
103. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 1994; 44:1523-1526.
104. Selmaj KW, Raines CS. Tumour necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988; 23:339-346.
105. Selmaj K, Raine CS, Farooq M, Norton WT, Brosnan CF. Cytokine cytotoxicity against oligodendrocytes: Apoptosis induced by lymphotoxin. J Immunol 1991; 147:1522-1529.
106. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80: 695-705.
107. Yu M, Johnson JM, Tuohy VK. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: A basis for peptide-specific therapy after onset of clinical disease. J Exp Med 1996; 183:1777-1788.
108. Maeda Y, Solanky M, Mennona J, Dowling P. Platelet derived growth factor receptor-positive oligodendroglia are frequent in multiple sclerosis lesions. Neurology 2000; 54:124.
109. Cho ES, Sharer LR, Prineas JW. Deposition of activated complement on myelin engaged by macrophages in evolving MS lesions. J Neuropathol Exp Neurol 2000; 59:431.
110. Schluesener HJ, Sobel RA, Linington C, Weiner HL. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 1987; 139:4016-4021.
111. Ludwin SK. Chronic demyelination inhibits remyelination in the central nervous system: An analysis of contributing factors. Lab Invest 1980; 43:382-387.
112. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000; 47:707-717.
113. Ulvestad E, Williams K, Vedeler C, Antel J, Nyland H, Mörk S, Matre R. Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG. J Neurol Sci 1994; 121:125-131.
114. Storch MK, Stefferl A, Brehm U, Weissert R, Wallström E, Kerschensteiner M, Olsson T, Linington C, Lassmann H. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998; 8:681-694.
115. Bernard CCA, Johns TG, Slavin A, Ichikawa M, Ewing C, Liu J, Bettadapura J. Myelin oligodendrocyte glycoprotein: A novel candidate autoantigen in multiple sclerosis. J Mol Med 1997; 75:77-88.
116. Linington C, Lassmann H. Antibody responses in chronic relapsing experimental allergic encephalomyelitis: Correlation of serum demyelinating activity with antibody titre to MOG. J Neuroimmunol 1987; 17:61-69.
117. D’Souza SD, Bonetti B, Balasingam V, Cashman NR, Barker PA, Troutt AB, Raine CS, Antel JP. Multiple sclerosis: Fas signalling in oligodendrocyte cell death. J Exp Med 1996; 184:2361-2370.
118. Raine CS. The Dale E McFarlin Memorial Lecture: The immunology of the multiple sclerosis lesion. Ann Neurol 1994; 36:561-572.
119. Antel JP, Williams K, Blain M, McRea E, McLaurin J. Oligodendrocyte lysis by CD4+ T cells independent of tumour necrosis factor. Ann Neurol 1994; 341-348.
120. van der Maesen K, Hinojoza JR, Sobel BS. Endothelial cell class II major histocompatability complex molecule expression in stereotactic brain biopsies of patients with acute inflammatory/demyelinating conditions. J Neuropathol Exp Neurol 1999; 58(4):346-358.
121. Sobel RA, Blanchette BW, Bhan AK, Colvin RB. The immunopathology of acute experimental allergic encephalomyelitis: II. Endothelial cell Ia expression increases prior to inflammatory cell infiltration. J Immunol 1984; 132:2402-2406.
122. Dowling P, Shang G, Raval S, Menonna J, Cook S, Husar W. Involvement of CD95 the (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 1996; 184:1513-1518.
123. Vartanian T, Li Y, Zhao M, Stefansson K. Interferon-γ-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol Med 1995; 1(7):732-743.
124. Traugott U, Lebon J. Interferon-γ and Ia antigen are present on astrocytes in active chronic multiple sclerosis lesions. Neurol Sci 1988; 84:257-264.
125. Cammer W, Bloom BR, Norton WT, Gordon S. Degradation of basic protein in myelin by neutral proteases secreted by stimulated macrophages: A possible mechanism of inflammatory demyelination. Proc Natl Acad Sci USA 1978; 75:1554-1558.
126. Hartung H-P, Rieckmann P. Pathogenesis of immune-mediated demyelination in the CNS. In: Riederer P et al, eds. Springer Medicine, vol 5. Wien, New York: Springer, 1997, pp 173-181.
127. Link J, Söderström M, Olsson T, Bo H, Ljungdahl A, Link H. Increased transforming growth factor-ß, interleukin-4, and interferon-t in multiple sclerosis. Ann Neurol 1994; 36:379-386.
128. Hickey WF, Kimura H. Perivascular microglia cells of the CNS are bone marrow derived and present antigen in vivo. Science 1988; 239:290-292.
129. Olsson T. Role of cytokines in multiple sclerosis and experimental autoimmune encephalomyelitis. Eur J Neurol 1994; 1:7-9.
130. Wekerle H, Linington C, Lassmann H, Meyermann R. Cellular immune reactivity within the CNS. Trends Neurosci 1986; 9:271-277.
131. Westland KW, Pollard JD, Sander S, Bonner JG, Linington C, McLeod JG. Activated nonneural specific T cells open the blood-brain barrier to circulating antibodies. Brain 1999; 122:1283-1291.
132. Karni A, Bakimer-Kleiner R, Abramsky O, Ben-Nuan A. Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch Neurol 1999; 56(3)311-315.
133. Wucherpfennig KW, Catz I, Hausmann S, et al. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients: Identity of key contact residues by the B-cell and T-cell epitopes. J Clin Invest 1997; 100:1114-1122.
134. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: A study of 113 cases. Brain 1999; 122:2279-2295.
135. Wolswijk G. Oligodendrocyte survival, loss and birth in lesions of chronic-stage multiple sclerosis. Brain 2000; 123:105-115.
136. LaGanke CC, Freeman DW, Whitaker JN. Cross-reactive idiotypy in cerebrospinal fluid immunoglobulins in multiple sclerosis. Ann Neurol 2000; 47:87-92.
137. Merrill JE, Benveniste EN. Cytokines in inflammatory brain lesions: Helpful and harmful. Trends Neurosci 1996; 19:331-338.
138. Benveniste EN. In Aggarawal B, Puri R eds. Human Cytokines: Their Role in Research and Therapy. Oxford, UK: Blackwell, 1995, pp 195-216.
139. Evangelou N, Konz D, Palace J, Esiri MM, Mathews PM. Relating regional axonal loss in the normal appearing white matter to distant lesions: A pathological study in multiple sclerosis. Mult Scler 1999; 5(suppl 2):S2.
140. Jensen MA, Dayal AS, Arnason BGW. Immune deviation from a TH1 toward a TH2-type T-cell response occurs during recovery from monophasic experimental autoimmune encephalomyelitis. Ann Neurol 1996; 40:552.
141. Zeine R, Freedman MS, Pon R, Nguyen V. Mechanism of gamma-delta T-cell cytotoxicity in multiple sclerosis. Ann Neurol 1996; 40:555.
142. Fu I, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998; 121:103-113.
143. McDonnell GV, Graham CA, McMillan SA, Middleton D, Hawkins SA. Primary progressive multiple sclerosis (PPMS) as a discrete disease. Mult Scler 1998; 4:356.
144. Ozenci MV, Kouwenhoven MCM, Huang YM, Kivisakk P, Link H. The proinflammatory cytokines TNF-a and IL-6 in MS. Mult Scler 1998; 4:345.
145. Nicholas RS, Compston DAS, Wing MG. Microglia support the survival of '‘stressed’’ oligodendrocytes. Mult Scler 1998; 4:346.
146. Tortorella C, Rocca MA, Codella M, Gasperini C, Capra R, Pozzilli C, Filippi M. Disease activity in multiple sclerosis studied with weekly triple dose magnetic resonance imaging. Mult Scler 1998; 4:303.
147. Weissert R, Wallström E, Storch MK, Stefferl A, Lorentzen J, Lassmann H, Linington C, Olsson T. MHC haplotype-dependent regulation of the clinical profile and lesional pathology of myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis in rats. Mult Scler 1998; 4:277.
148. Perry VH. Axonal damage in a model of an MS lesion. Mult Scler 1998; 4:278.
149. Jellinger K, Boltzman L. Neuropathology of '‘MS’’ encephalopathy. Mult Scler 1998; 4: 287.
150. Evangelou N, Esiri M, Palace J, Mathews PM. A quantitative pathological study of axonal loss in the corpus callosum in multiple sclerosis. Mult Scler 1998; 4:287.
151. Tan IL, Barkhof F, Hoogenraad FGC, Hofman MBM, Reichenbach JR, Manoliu RA. MR venography in multiple sclerosis. Mult Scler 1998; 4:302.
152. van Waesberghe JHTM, Kamphorst W, De Groot CJA, van Walderveen MAA, Castelijns JA, Ravid R, et al. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999; 46:747-754.
153. Bashir K, Layton B, Whatley W, Whitaker JN. Clinical and laboratory features of primary progressive and secondary progressive multiple sclerosis. Ann Neurol 1998; 44:466.
154. Chen C-J, Chu N-S, Lu C-S, Sung C-Y. Serial magnetic resonance imaging in patients with Balos concentric sclerosis: natural history of lesion development. Ann Neurol 1999; 46:651-656.
155. Kesselring J, Miller DH, Robb SA, Kendall BE, Moseley IF, Kingsley D, du Boulay EP, McDonald WI. Acute disseminated encephalomyelitis: MRI findings and the distinction from multiple sclerosis. Brain 1990; 113:291-302.
156. Eblen F, Poremba M, Grodd W, Optiz H, Roggendorf W, Dichgans J. Myelinclastic diffuse sclerosis (Schilders disease): Cliniconeuroradiologic correlations. Neurology 1991; 41:589-591.
157. Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C. Animal models. Ann Neurol 1994; 36:547-553.
158. Best PV. Acute polyradiculoneuritis associated with demyelinated plaques in the central nervous system: Report of a case. Acta Neuropathol (Berl) 1985; 67:230-234.
159. Söderström M, Hillert J, Link J, Navikas H, Frederiksen S, Link H. Expression of IFN-γ, IL-4 and TGF-a in multiple sclerosis in relation to HLA-Dw2 phenotype an stage of disease. Mult Scler 1995; 1:173-180.
160. Waxman SG. Editorial: Peripheral nerve abnormalities in multiple sclerosis. Muscle Nerve 1993; 16:1-5.
161. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS, Antel JP, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998; 121:1469-1477.
162. Lassmann H. Mechanisms of demyelination in multiple sclerosis. Mult Scler 1999; 5:51.
163. Youl BD, Kermode AG, Thompson AJ, et al. Destructive lesions in demyelinating disease. J Neurol Neurosurg Psychiatry 1991; 54:288-292.
164. Harpey JP, Renault F, Foncin JF, Gardeur D, Horn YE, Roy C. Démyélinisation aiguë pseudotumorale a poussées régressives. Arch Fr Pédiatr 1983; 40:407-409.
165. Dowling P, Husar W, Menonna J, Donnenfeld H, Cook S, Sidhu M. Cell death and birth in multiple sclerosis brain. J Neurol Sci 1997; 149:1-11.
166. Karussis D, Leker RR, Ashkenazi A, Abramsky O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: Do they represent a new nosological entity? Ann Neurol 1998; 44:629-634.
167. Mews I, Bergmann M, Bunkowski S, Gullotta F, Brück W. Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Mult Scler 1998; 4:55-62.
168. Dal Canto MC, Wiśniewski HM, Johnson AB, Brostoff SW, Raine CS. Vesicular disruption of myelin in autoimmune demyelination. J Neurol Sci 1975; 24:313-319.
169. Ghatak NR. Occurrence of oligodendrocytes within astrocytes: A form of emperipolesis. J Neuropathol Exp Neurol 1990; 49:285.
170. Dahl D, Perides G, Bignami A. Axonal regeneration in old multiple sclerosis plaques: Immunohistochemical study with monoclonal antibodies to phosphorylated and non-phosphorylated neurofilament proteins. Acta Neuropathol 1989; 79:154-159.
171. Aarli JA, Aparicio SR, Lumsden CE, Tönder O. Binding of normal human IgG to myelin sheaths, glia and neurons. Immunology 1975; 28:171-186.
172. Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci 1998; 18:601-609.
173. Wolswijk G. Oligodendrocyte regeneration in the adult rodent CNS and the failure of this process in multiple sclerosis (review). Prog Brain Res 1998; 117:233-247.
174. Compston A. Remyelination in multiple sclerosis: A challenge for therapy. The 1996 European Charcot Foundation Lecture. Mult Scler 1997; 3:51-70.
175. Franklin RJM, Blakemore WF. To what extent is oligodendrocyte progenitor migration a limiting factor in the remyelination of multiple sclerosis lesions? Mult Scler 1997; 3:84-87.
176. Gilson J, Blakemore WF. Failure of remyelination in areas of demyelination in the spinal cords of old rats. Neuropathol Appl Neurobiol 1993; 19:173-181.
177. Greer JM, Csurhes PA, Cameron KD, McCombe PA, Good MF, Pender MP. Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain 1997; 120:1447-1460.
178. Franklin RJM, Bayley SA, Blakemore WF. Transplanted CG4 cells (an oligodendrocyte progenitor cell line) survive, migrate and contribute to repair of areas of demyelination in x-irradiated and damaged spinal cord, but not in normal spinal cord. Exp Neurol 1996; 137: 263-276.
179. Scolding NJ, Rayner PJ, Susman J, Shaw C, Compston DAS. A proliferative adult human oligodendrocyte progenitor. Neuroreport 1995; 6:441-445.
180. Ishikawa M, Tsukamoto T, Yamamoto T. Long-term cultured astrocytes inhibit myelin formation, but not axonal growth in the co-cultured nerve tissue. Mult Scler 1996; 2:91-95.
181. Rosenbluth J. Glial transplantation in the treatment of myelin loss or deficiency. In: Bostock H, Kirkwood PA, Pullen AH eds. The Neurobiology of Disease: Contributions from Neuroscience to Clinical Neurology. Cambridge, UK: Cambridge University Press, 1996, pp. 124-148.
182. Rodriguez M, Miller DJ, Lennon VA. Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 1996; 46:538-545.
183. Carroll WM, Jennings AR. In vivo CNS remyelination: HNK-1 labels newly differentiated oligodendrocytes but not precursors. J Neurocytol 1993; 22:583-589.
184. Carroll WM, Jennings AR, Mastaglia FL. The origin of remyelinating oligodendrocytes in antiserum-mediated demyelinative optic neuropathy. Brain 1990; 113:953-957.
185. Franklin RJM, Blakemore WF. Transplanting oligodendrocyte progenitors into the adult CNS. J Anat 1997; 190:23-33.
186. Vanguri P, Koski CL, Silverman B, Shin ML. Complement activation by isolated myelin: Activation of classical pathway in the absence of myelin specific antibodies. Proc Natl Acad Sci USA 1982; 79:3290-3294.
187. Moore GRW, Berry K, Oger JJF, Nugent RA, Graeb DA, Mackay AL. Baló‘s concentric sclerosis with bands of normal myelin in a patient with an eight year history of multiple sclerosis. J Neuropathol Exp Neurol 1996; 55:657.
188. Kira J, Kanai T, Nishimura Y, Yamasaki K, Matsushita S, Kawano Y, Hasuo K, Tobimatsu S, Kobayashi T. Western versus Asian types of multiple sclerosis: Immunogenetically and clinically distinct disorders. Ann Neurol 1996; 40:569-574.
189. Cammer W, Brosnan CF, Basile C, Bloom BR, Norton WT. Complement potentiates the degradation of myelin proteins by plasmin: Implications for a mechanism of inflammatory demyelination. Brain Res 1986; 364:91-101.
190. Tabi Z, McCombe PA, Pender MP, Cyong JC, Witkins S, Rieger B, Barbarese E, Good RA, Day NK. Antibody-independent complement activation by myelin via classical pathway. J Exp Med 1982; 155:587-598.
191. + encephalitogenic T cells. Eur J Immunol 1994; 24:2609-2617.